Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information

CIO (Greater China)



Dr. Fei Jiang is the Chief Investment Officer (Greater China) of CMS Group (0867.HK). He’s in charge of CMS’ strategic investment as well as business development in Greater China Region.

Dr. Jiang got his Ph.D. degree in chemical engineering from Syracuse University, New York at 2006, after receiving his bachelor degree, also in chemical engineering, from East China University of Science and Technology, Shanghai at 1998. 

After graduation, he joined Cell Genesys at South San Francisco, California, to develop cancer cell-based immunotherapy products, and AlphaVax Inc. at Research Triangle Park, North Carolina, to develop RSV and CMV vaccines. 

Dr. Jiang returned to China and joined in 3SBio (1530.HK) at 2010. He served as R&D Manager, and later R&D Director till 2013. He shifted his role to BD Director since 2013, and took care of business development and strategic alliance management for 3SBio. He joined in healthcare investment business since 2017, and served as the Executive Director of Guijing Capital and Sinopharm Capital, and the Managing Director of Aplus Capital successively.